Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Aripiprazole Oral Acceptability Trial

This study has been completed.
Sponsor:
Collaborator:
Otsuka America Pharmaceutical
Information provided by:
Otsuka Pharmaceutical Development & Commercialization, Inc.
ClinicalTrials.gov Identifier:
NCT00101569
First received: January 12, 2005
Last updated: November 7, 2013
Last verified: July 2008

January 12, 2005
November 7, 2013
March 2004
March 2005   (final data collection date for primary outcome measure)
acceptability
Not Provided
Complete list of historical versions of study NCT00101569 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Aripiprazole Oral Acceptability Trial
Aripiprazole Oral Acceptability Trial

The purpose of this trial is to study liquid aripiprazole in patients with stable schizophrenia.

Not Provided
Interventional
Phase 3
Allocation: Non-Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Schizophrenia
  • Drug: Aripiprazole
    Tablets, Oral, 15 -30 mg, once daily, 2 weeks (days 1 -14).
    Other Name: Abilify
  • Drug: Aripiprazole
    Oral Solution, Oral, 15-30 ml, once daily, 1 week (days 15 -21).
    Other Name: Abilify
  • Experimental: A1
    Intervention: Drug: Aripiprazole
  • Experimental: A2
    Intervention: Drug: Aripiprazole
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
59
March 2005
March 2005   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Stable patients currently receiving aripiprazole or other antipsychotic medications.
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00101569
CN138-091
Not Provided
Not Provided
Otsuka Pharmaceutical Development & Commercialization, Inc.
Otsuka America Pharmaceutical
Study Director: Bristol-Myers Squibb Bristol-Myers Squibb
Otsuka Pharmaceutical Development & Commercialization, Inc.
July 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP